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Abstract
Background. The association between parathyroid hor-
mone (PTH) level and mortality in dialysis patients is con-
troversial. We hypothesized that wasting, a common condi-
tion potentially related to adynamic bone disease, modifies
the association of PTH with mortality and cardiovascular
events (CVE), respectively.
Methods.Weanalysed datafrom1255 diabetic haemodial-
ysis patients, participating in the German Diabetes and
Dialysis Study between 1998 and 2004. The patients were
stratified by the presence or absence of wasting (albumin
≤3.8 versus albumin >3.8 g/dL; BMI ≤23 versus BMI
>23 kg/m2). Using Cox regression analyses, we calculated
the risks of (1) all-cause mortality and (2) CVE accord-
ing to baseline PTH levels. All analyses were adjusted
for age, sex, atorvastatin treatment, duration of dialysis,
comorbidity, HbA1c, phosphate, calcium, blood pressure,
haemoglobin and C-reactive protein.
Results. Patients had a mean age of 66 ± 8 years, and
54% were male. Among patients without wasting (albumin
>3.8 g/dL, n = 586), the risks of death and CVE during
4 years of follow-up significantly increased by 23% and
20% per unit increase in logPTH. Patients in the highest
PTH tertile had a 74% higher risk of death (HRadj 1.74,
95% CI 1.27–2.40) and a 49% higher risk of CVE (HRadj
1.49, 95% CI 1.05–2.11) compared to patients in the lowest
PTH tertile. In contrast, no effect was found in patients
with wasting. Accordingly, additional analyses in strata of
BMI showed that PTH significantly impacted on death and
CVE [HR(logPTH)adj 1.15 and 1.14, respectively] only in
patients without, but not in patients with, wasting.
Conclusions. Wasting modifies the association of PTH
with adverse outcomes in diabetic dialysis patients. High
PTH levels are of concern in the patients without wasting,
while the effect of PTH on mortality is nullified in the
patients with wasting.
Keywords: cardiovascular events; haemodialysis; mortality; parathyroid
hormone; wasting
Introduction
Parathyroid hormone (PTH) modulates calcium and phos-
phate homeostasis [1–3]. Disorderswithexcess PTHsecre-
tion, such as primary and secondary hyperparathyroidism,
can lead to bone disease and vascular calcification. Ac-
cordingly, a high PTH was found to be associated with
high risks of cardiovascular events (CVE) and mortality
in the general population [4,5]. In patients with chronic
kidney disease (CKD), however, the association is less
clear: similar results were reported for patients with mod-
erate to severe CKD [6], but studies in dialysis patients
are controversial. While some studies indicated higher
risks of death with increased PTH levels [7–10], other
investigations either found no association [11] or a low
PTH being related to a greater risk of adverse outcomes
[12–14].
In CKD and end-stage renal disease (ESRD), wasting
is a common problem, representing a severe and com-
plex process of muscle loss, poor food intake, inflamma-
tion and the development of comorbidities [15,16]. Patients
with diabetes mellitus are especially affected by the syn-
drome, which was shown to be associated with a high
mortality [17]. Wasting was furthermore found to be re-
lated to adynamic bone disease, which is a severe state of
renal osteodystrophy, and characterized by low levels of
PTH, lack of bone cell activity and a low bone turnover
[18,19]. This, in turn, was reported to be linked to in-
creased fracture risks and higher cardiovascular compli-
cations such as aortic stiffening and arterial calcification
[20,21].
Given the interrelations of wasting with PTH
metabolism, we hypothesized that wasting modifies the
association of PTH with adverse outcomes in long-term
dialysis patients with diabetes mellitus. We therefore as-
sessed the effect of PTH on all-cause mortality and CVE in
1255diabetichaemodialysispatientsparticipatinginthe4D
study (the German Diabetes and Dialysis Study), stratified
by the presence of wasting.
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Subjects and methods
Study design and participants
The 4D study methodology has previously been reported in detail [22].
Briefly, the 4D study was a prospective randomized controlled trial in-
cluding 1255 patients with type 2 diabetes mellitus, 18–80 years, and the
previousdurationof haemodialysisof <2years. Between March 1998and
October 2002, patients were recruited in 178 participating dialysis centres
in Germany. After a run-in period of 4 weeks, the patients were randomly
assigned to double-blind treatment with either 20 mg atorvastatin (n =
619) or placebo (n = 636) once daily. Study visits took place three times
beforerandomization(visits1–3),atrandomization(visit4)andat4weeks
(visit5)andevery6months(visit6,etc.)afterrandomizationuntilthedate
of death, censoring or end of the study in March 2004. The primary end-
point of the 4D study was defined as a composite of death from cardiac
causes, non-fatal myocardial infarction and stroke, whichever occurred
first. Secondary endpoints included death from all causes, sudden death,
all myocardial infarctions and stroke. The 4D study endpoints were cen-
trally adjudicated by three members of the endpoint committee blinded to
study treatment and according to pre-defined criteria [23].
For the present analysis, all-cause mortality and combined CVE in-
cluding cardiac death, myocardial infarction and stroke were chosen to be
separate outcome measures and were based on the primary judgement of
the endpoint committee during the 4D study. The study was approved by
themedicalethicalcommittee,andallpatientsgavetheirwritten informed
consent before inclusion.
Data collection
Information on age, gender and smoking status was obtained through
patient interviews. Smoking status was classified as never, former or cur-
rent. Comorbidities, including the presence of coronary artery disease
and congestive heart failure, as well as the duration of diabetes melli-
tus and dialysis treatment, were reported by the patients’ nephrologists.
Blood pressure was measured in a sitting position. Body mass index was
calculated as weight (kg) divided by height (m) squared. All laboratory
measurementsofthe4DstudywereperformedcentrallyattheDepartment
of Clinical Chemistry, University of Freiburg, Germany. Concentrations
of serum albumin, C-reactive protein, haemoglobin, calcium, phosphate,
LDL cholesterol, glycated haemoglobin A1c and intact PTH were mea-
sured in blood samples taken at baseline at study visit 3 (1 week before
randomization). Measurements of intact PTH were performed by the PTH
STAT test on an Elecsys 2010 analyser (Roche Diagnostics Mannheim,
Germany). Albumin was measured photometrically using the anionic dye
bromcresol green on a Roche Modular clinical chemistry analyser (Roche
Diagnostics Mannheim, FRG). Calibrators and quality control materials
were also obtained by Roche Diagnostics. Inter-assay coefficients of vari-
ance were <5%. All blood samples were taken before the start of dialysis
sessions and administration of drugs.
Statistical analysis
The study population was divided into two groups, according to the pres-
ence or absence of wasting. Since wasting represents an unspecific con-
dition with a number of contributing factors, and due to the absence of
guidelines for classification, we used albumin and furthermore BMI as
commonly available markers in line with suggestions recently being given
by an expert panel [15]. Therefore, wasting was defined by albumin levels
≤3.8 g/dL, and in additional analyses by a BMI ≤23 kg/m2. Continuous
variables were expressed as mean with standard deviation or median with
an interquartile range (IQR) as appropriate, and categorical variables were
expressed as percentages.
Associations of PTH with all-cause mortality and CVE were assessed
by absolute (incidence) rates and by relative risks derived from Cox re-
gression analyses, i.e. hazard ratios (HRs) and corresponding 95% confi-
dence intervals (CI). The Cox regression analyses were adjusted for the
confounders age, sex, atorvastatin treatment, duration of haemodialysis,
coronary artery disease, congestive heart failure, peripheral vascular dis-
ease, systolic blood pressure, glycaemic control as represented by HbA1c
and levels of calcium, phosphate, haemoglobin and C-reactive protein.
The following analyses were performed in detail. First, the study pop-
ulation was divided into tertiles according to the PTH levels at baseline.
Associations of the PTH tertiles with mortality and CVE were assessed
within the categories of the presence or absence of wasting (albumin ≤3.8
Table 1. Baseline patient characteristics, presented according to the pres-
ence/absence of wasting, defined by albumin ≤/> 3.8 g/dL; study popu-
lation n = 1255
Albumin (g/dL)
≤3.8 >3.8
Characteristic (wasting, n = 668) (no wasting, n = 587)
Age (years) 67 (8) 65 (8)
Gender (% men) 47.5 61.3
Atorvastatin 50.3 51.1
treatment (%)
Systolic BP (mmHg) 145 (23) 146 (21)
Smoker/ex-smoker (%) 36.1 45.3
BMI (kg/m2) 27.7 (5.1) 27.4 (4.5)
Duration of diabetes 18.2 (8.8) 18.0 (8.8)
(years)
Time on dialysis 7.3 (6.3) 9.4 (7.3)
(months)
History of
CAD (%) 30.2 28.4
CHF (%) 38.6 31.7
PVD (%) 46.9 42.1
Laboratory parameters
PTH (pg/mL) 90 (98) 116 (138)
LDL cholesterol 124 (31) 128 (29)
(mg/dL)
Haemoglobin (g/dL) 10.7 (1.4) 11.1 (1.3)
HbA1c (%) 6.8 (1.3) 6.7 (1.2)
C-reactive protein 13.9 (24.0) 7.6 (10.3)
(mg/L)
Calcium (mmol/L) 2.3 (0.2) 2.3 (0.2)
Phosphate (mmol/L) 5.9 (1.7) 6.1 (1.5)
Values are presented as means (SD) or %.
To convert serum albumin in g/dL to g/L, multiply by 10; PTH in pg/mL
to ng/L, multiply by 1; LDL cholesterol in mg/dL to mmol/L, multiply by
0.02586; haemoglobin in g/dL to mmol/L, multiply by 0.62.
PTH = parathyroid hormone; BP = blood pressure; BMI = body mass
index; CAD = coronary artery disease, CHF = congestive heart fail-
ure; PVD = peripheral vascular disease; LDL = low-density lipoprotein;
HbA1c = haemoglobin A1c;
versus albumin >3.8 g/dL). Second, baseline PTH was analysed as a con-
tinuous variable (log transformed) with regard to the adverse outcomes.
Third,inordertotesttherobustnessofourresults,additionalanalyseswere
performed in strata of BMI as a further marker to classify the presence
(BMI ≤23 kg/m2)o ra b s e n c e( B M I>23 kg/m2) of the wasting syndrome.
WithintheBMIgroups,analyseson theassociation ofPTH with mortality
and CVE were performed according to the description given above. Simi-
larly, PTH was investigated both as continuous and as categorical variable
(tertiles).
All P-values are reported two-sided. Analyses were performed using
SPSS version 16.0.
Results
Patient characteristics
Between March 1998 and October 2002, a total of 1255
patients entered the 4D study. Of those, 1248 patients had
a baseline PTH measurement. The mean follow-up period
was 3.96 years (median 4.0 years) on atorvastatin and 3.91
years (median 4.08 years) on placebo. During the follow-
up, 617 patients died. Furthermore, 469 patients reached
the endpoint of combined CVE.
In the study population (n = 1255), the mean age was
65.7 ± 8.3 years, and 54% of the patients were male. TheThe association between parathyroid hormone and mortality in dialysis patients is modified by wasting 3153
Fig. 1. Kaplan–Meier curves for the time to all-cause mortality in patients with wasting (albumin ≤3.8 g/dL, A) and patients without wasting (albumin
>3.8 g/dL, B); patients were grouped into tertiles of parathyroid hormone levels with the lowest tertile (tertile 1) serving as the reference group.
mean baseline PTH level was 102 ± 119 pg/mL (median
PTH 70 pg/mL; interquartile range 36–127 pg/mL). No
significant differences were noted between the atorvastatin
andplacebogroups.Thebaselinepatientcharacteristicsare
shown in Table 1.
PTH, wasting and all-cause mortality
Within the whole study population, the mortality risks for
patients in the second or third PTH tertile were not ma-
terially different compared to the reference of patients in
the lowest PTH tertile (adjusted HRTertile2 1.17, 95% CI
0.95–1.44; adjusted HRTertile3 1.19, 95% CI 0.96–1.47). In-
vestigating the hypothesis of effect modification by wast-
ing, the analyses on PTH and mortality were stratified by
wasting as defined by baseline albumin levels. In patients
without wasting (albumin >3.8 g/dL, n = 586), the abso-
lute mortality rate during 4 years of follow-up was 15 per
100 person years (py). All-cause mortality increased step-
wise with higher PTH levels: it was 11/100 py for patients
in the lowest tertile with a PTH ≤46.3 pg/mL, 15/100 py in
patients with a PTH between 46.3 and 106 pg/mL (second
tertile) and 17/100 py in patients with a PTH >106 pg/mL
(third tertile) (Figure 1B and Table 2). In unadjusted Cox
regression analyses using PTH as a continuous variable,
the relative risk of death increased significantly by 17%
per unit increase in log-transformed PTH (HR 1.17, 95%
CI 1.04–1.31). The association was even stronger in multi-
variate analyses with a 23% increase in mortality per unit
increase in log-transformed PTH (HR 1.23, 95% CI 1.09–
1.39). With multivariate Cox regression models using PTH
as a categorical variable, patients in the second PTH tertile
had a 37% higher risk of death compared to those in the
lowest tertile. Patients with highest PTH levels (third ter-
tile)hadthehighestmortality,beingsignificantlyincreased
by 74% as compared to patients in the lowest PTH tertile
(Table 2). Similar results were found in additional analyses
using a BMI >23 kg/m2 to define the absence of wasting.
All-cause mortality significantly rose by 15% per unit in-
crease in log-transformed PTH in patients without wasting.
In contrast, in patients with the disease state expectedly
showing a high incidence of death (the absolute mortality
rate was 21/100 py), no association of PTH with mortality
was found: death rates were similar across the tertiles of
PTH, both in the analyses using albumin and BMI for the
definition of wasting.
PTH, wasting and the risk of CVE
The absolute rate for CVE was 21/100 py in patients with
wasting, and 15/100 py in patients without wasting as de-
fined by baseline albumin levels.
When relative risks were investigated, crude Cox regres-
sion analyses in patients without the wasting syndrome (al-
bumin > 3.8 g/dL) revealed a significant 19% increase in
CVE (HR 1.19, 95% CI 1.04–1.36) per unit increase in log-
transformed PTH. The strong association persisted after
multivariable adjustments (HR 1.20, 95% CI 1.04–1.38).
In analyses using PTH as a categorical variable, patients
inthehighestPTHtertilehada49%higherriskofCVE(HR
1.49,95%CI1.05–2.11)ascomparedtopatientsinthelow-
est PTH tertile. When the absence of wasting was defined
by a BMI >23 kg/m2 in additional analyses, similar results
were found. The risk of CVE increased by 14% (HR 1.14,
95% CI 1.02–1.28) per unit increase in log-transformed
PTH. Furthermore, patients of the second and third PTH
tertile were 19% and 31% more likely to exhibit CVE as
compared to the lowest tertile, respectively (Table 3).
Discussion
This study investigated the role of wasting in the associ-
ation of PTH levels with adverse outcomes in long-term
dialysis patients with type 2 diabetes mellitus. We found
that wasting modified the relation of PTH with all-cause
mortality and CVE in 1255 diabetic haemodialysis patients
participating in the 4D study, a prospective cohort with a3154 C. Drechsler et al.
Table 2. Parathyroid hormone and risk of all cause mortality and CVE in strata of wasting, as defined by albumin levels ≤/>3.8 g/dL; n = 1248
Wasting albumin n = 662 No wasting albumin n = 586
≤3.8 g/dL >3.8 g/dL
PTH tertiles PTH tertiles
Tertile 1 Tertile 2 Tertile 3 Tertile 1 Tertile 2 Tertile 3
PTH ≤ PTH > 46.3 PTH > PTH ≤ PTH > 46.3 PTH >
46.3 pg/mL ≤ 106 pg/mL 106 pg/mL 46.3 pg/mL ≤ 106 pg/mL 106 pg/mL
Variables n = 239 n = 231 n = 192 n = 177 n = 185 n = 224
All-cause mortality
Incidence rate per 100 py 21 22 18 11 15 17
Crude hazard ratio (95% CI) 1a 1.07 (0.84–1.38) 0.87 (0.67–1.15) 1a 1.32 (0.96–1.81) 1.48 (1.10–1.99)
P = 0.58 P = 0.33 P = 0.08 P = 0.01
Adjustedb hazard ratio (95% CI) 1a 1.07 (0.82–1.39) 0.86 (0.63–1.16) 1a 1.37 (0.98–1.92) 1.74 (1.27–2.40)
P = 0.64 P = 0.32 P = 0.07 P = 0.001
Adjustedb hazard ratio 1.03 (0.90–1.17) 1.23 (1.09–1.39)
(95% CI) for log PTH P = 0.67 P = 0.001
as cont. variable
Cardiovascular events
Incidence rate per 100 py 20 22 19 13 13 18
Crude hazard ratio (95% CI) 1a 1.10 (0.82–1.48) 0.97 (0.71–1.32) 1a 1.05 (0.73–1.50) 1.44 (1.04–1.99)
P = 0.52 P = 0.85 P = 0.81 P = 0.03
Adjustedb hazard ratio (95% CI) 1a 1.20 (0.88–1.65) 1.05 (0.74–1.48) 1a 1.01 (0.69–1.48) 1.49 (1.05–2.11)
P = 0.25 P = 0.80 P = 0.94 P = 0.03
Adjustedb hazard ratio 1.09 (0.94–1.26) 1.20 (1.04–1.38)
(95% CI) for log PTH P = 0.24 P = 0.012
as cont. variable
To convert serum albumin in g/dL to g/L, multiply by 10; PTH in pg/mL to ng/L, multiply by 1.
PTH = parathyroid hormone.
aPatients with a PTH ≤46.3 pg/mL were used as the reference group.
bMultivariate analyses: adjustments were made for age, sex, atorvastatin treatment, duration of haemodialysis, coronary artery disease, congestive heart
failure, peripheral vascular disease, systolic blood pressure, glycaemic control as represented by HbA1c and levels of calcium, phosphate, haemoglobin
and C-reactive protein.
high incidence of pre-specified and centrally adjudicated
endpoints. High levels of PTH were associated with in-
creased mortality and CVE in patients without wasting, but
not in patients with the disease state. Among patients with-
out wasting, those in the highest PTH tertile had 74% and
49% higher risks of death and CVE, respectively, as com-
pared to patients in the lowest PTH tertile. In contrast, no
effect of PTH on adverse outcomes was seen in patients
with the wasting syndrome.
This study is the first that investigated the association of
PTH with adverse outcomes in dialysis patients, taking into
accountpotentialeffectmodificationbywasting.Itrevealed
that the negative effects of a high PTH are only observed in
relatively healthy patients without the wasting syndrome,
but do not appear in those suffering from the disease state.
Our data contribute to explain divergent results found for
the relation of PTH with adverse outcomes in previous
studies of dialysis patients. Data from the Dialysis Out-
comes and Practice Patterns Study for example showed that
mortality was higher among patients with high PTH lev-
els >600 pg/mL [9], and further large observational stud-
ies among dialysis patients reported higher risks of death
with increased PTH levels [7,8,10]. However, other studies
found no association [11], or that a low PTH was associ-
atedwithanincreasedmortality[12–14].Apartfrompartly
methodological explanations including different follow-up
times, our study adds important new knowledge showing
that the impact of PTH on adverse outcomes depends on
the disease state of the population studied. Furthermore, it
provides a link to the results and the understanding of PTH
metabolism in the general population and CKD patients of
earlier stages. These patients in general are healthier and
suffer to a much lesser extent from wasting. It is there-
fore not surprising that in these populations many studies
indicated a clear association of hyperparathyroidism with
increased mortality [4–6,24], which was even reported to
be independent of 25-hydroxy-vitamin D status, bone mass
and renal function [24].
Mechanisms by which a high PTH may affect mortal-
ity include impaired insulin sensitivity [25], glucose in-
tolerance [26] and abnormal lipid metabolism [27]. Other
mechanisms reported in the literature refer to bone marrow
fibrosis [28] with ineffective erythropoiesis [29] and ab-
normal immune function [30]. Furthermore, PTH has been
shown to directly affect vascular smooth muscle cells and
ventricular myocytes [31], with the potential to impair car-
diac energy production, and the accumulation of calcium
in the myocardium [32]. Excess PTH was suggested to
play a role in the pathogenesis of myocardial hypertrophy
and fibrosis, vascular calcification, impaired endothelial
vasodilation and left ventricular diastolic filling dynam-
ics [33–37]. In this context, our finding of a high PTH
being associated with CVE in patients without wasting is
not surprising. In line with prior studies showing that high
PTH was related to the development of cardiovascular dis-
ease [38], including coronary heart disease [39], our dataThe association between parathyroid hormone and mortality in dialysis patients is modified by wasting 3155
Table 3. Parathyroid hormone and risk of all-cause mortality and CVE in strata of wasting, as defined by BMI ≤/> 23 kg/m2; n = 1248
Wasting BMI n = 189 No wasting BMI n = 1059
≤23 kg/m2 >23 kg/m2
PTH tertiles PTH tertiles
Tertile 1 Tertile 2 Tertile 3 Tertile 1 Tertile 2 Tertile 3
PTH PTH >46.3 PTH PTH PTH >46.3 PTH >106 pg/
≤ 46.3 pg/mL ≤106 pg/mL >106 pg/mL ≤46.3 pg/mL ≤106 pg/mL mL
Variables n = 76 n = 59 n = 54 n = 340 n = 357 n = 362
All-cause mortality
Incidence rate per 100 py 25 25 28 14 17 16
Crude hazard ratio (95% CI) 1a 0.99 (0.64–1.51) 1.13 (0.74–1.74) 1a 1.23 (0.99–1.54) 1.12 (0.89–1.39)
P = 0.95 P = 0.56 P = 0.07 P = 0.34
Adjustedb hazard ratio 1a 0.94 (0.58–1.54) 0.94 (0.58–1.53) 1a 1.27 (1.00–1.60) 1.28 (1.00–1.63)
(95% CI) P = 0.81 P = 0.80 P = 0.05 P = 0.05
Adjustedb hazard ratio 1.04 (0.84–1.28) 1.15 (1.04–1.27)
(95% CI) for log PTH P = 0.71 P = 0.005
as cont. variable
Cardiovascular events
Incidence rate per 100 py 23 21 30 15 17 17
Crude hazard ratio (95% CI) 1a 0.93 (0.55–1.57) 1.32 (0.81–2.17) 1a 1.11 (0.86–1.43) 1.14 (0.89–1.46)
P = 0.78 P = 0.26 P = 0.43 P = 0.30
Adjustedb hazard ratio 1a 0.80 (0.44–1.46) 1.01 (0.58–1.79) 1a 1.19 (0.91–1.56) 1.31 (1.00–1.72)
(95% CI) P = 0.46 P = 0.96 P = 0.20 P = 0.05
Adjustedb hazard ratio 1.12 (0.88–1.42) 1.14 (1.02–1.28)
(95% CI) for log PTH P = 0.35 P = 0.02
as cont. variable
To convert serum albumin in g/dL to g/L, multiply by 10; PTH in pg/mL to ng/L, multiply by 1.
PTH = parathyroid hormone.
aPatients with a PTH ≤46.3 pg/mL were used as the reference group.
bMultivariate analyses: adjustments were made for age, sex, atorvastatin treatment, duration of haemodialysis, coronary artery disease, congestive heart
failure, peripheral vascular disease, systolic blood pressure, glycaemic control as represented by HbA1c and levels of calcium, phosphate, haemoglobin
and C-reactive protein.
support the evidence that part of the adverse effects of
excess PTH result from its actions on the cardiovascular
system.
In patients with the wasting syndrome, no association
of PTH with mortality or CVE was found. Wasting is
common in patients with CKD and particularly present in
those with diabetes mellitus [40,41]. It represents a se-
vere and complex process of muscle loss, poor food intake,
inflammation and the development of comorbidities [15]
and is associated with a high mortality [17,42]. Malnutri-
tionandhypoalbuminaemia—characteristicsofthewasting
syndrome—have been found to be associated with ady-
namic bone disease, which is as a severe state of renal
osteodystrophy characterized by low levels of PTH and low
bone turnover [18,19,43,44]. It may therefore be that low
levels of PTH in patients with wasting represent a surrogate
of an underlying disease process, with a low PTH pos-
sibly reflecting an impaired secretion due to the ‘illness’
(i.e. wasting). The potential impact of wasting on bone
metabolism may be supported by further experimental ev-
idence: in vitro, inflammation has been shown to suppress
PTH [45,46]. Furthermore, leptin as a key anorexigenic
hormone was shown to have antiosteogenic properties and
todecreasebonemass[47].Additionally,weightlossthatis
frequently observed in wasting was reported to lower PTH
levels in humans [48]. Therefore, the suggested impact of
wasting on PTH metabolism may be a key reason to alter
associations of PTH with CVE and mortality in dialysis
patients. Finally, it could, however, also be argued that the
impact of wasting on mortality is so strong that it overshad-
ows the association of a high PTH with adverse outcomes.
Furtherresearchisclearlywarranted,withtheresultsofour
study indicating the need for stratification according to the
presence or absence of wasting in clinical evaluations of
bone metabolism.
Our study has potential limitations. It was a post hoc
analysis within a selected cohort of German patients with
type 2 diabetes mellitus on haemodialysis. Therefore, the
results cannot necessarily be extrapolated to other patient
populations. Yet it may be assumed that the results also
hold true for non-diabetic haemodialysis patients, suffer-
ing from wasting and PTH disorders, too. The group of
patients with wasting as defined by a BMI ≤23 kg/m2 in
our additional analyses was relatively small, and results
may become stronger with larger numbers of patients in
future studies. Furthermore, measurements of PTH might
have been compromised by the high susceptibility of the
hormone to pre-analytic processes. Levels of PTH, which
are known to be generally lower in diabetic as compared to
non-diabetic patients, therefore might have been addition-
ally lowered. However, as all samples were treated in the
same manner, pre-analytic processes are unlikely to have
affected our investigations, which focused on relative com-
parisons based on PTH tertiles. Finally, we did not have3156 C. Drechsler et al.
information on vitamin D levels, which potentially may
provide further insight into the mechanisms underlying the
associations seen.
The main strengths of this study include the long-term
follow-up, the high number of study participants and the
high incidence of pre-specified and centrally adjudicated
endpoints.
In conclusion, wasting modifies the association of PTH
with adverse outcomes in dialysis patients with type 2 di-
abetes mellitus. High levels of PTH were associated with
increased mortality and CVE in patients without wasting,
butnotinpatientswiththewastingsyndrome.Ourdatapro-
vide evidence that the effect of PTH on adverse outcomes
is markedly dependent on the patients’ disease states. We
therefore suggest that risk assessments of PTH should be
performed in strata of wasting. This may help clinicians in
the decision and evaluation of treatment options, with our
data suggesting that high PTH is of concern in relatively
healthy dialysis patients without wasting, while the effect
of PTH on mortality is nullified in patients with wasting.
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Abstract
Background.Cardiovasculardiseaseistheleadingcauseof
death in the chronic kidney disease (CKD) population. The
mechanisms of vascular damage are not fully understood.
The objective of this study was to prospectively investi-
gate the importance of novel mediators of vascular dam-
age, in conjunction with vascular calcification (VC), on
survival.
Methods. A total of 134 subjects [60 haemodialysis (HD),
28 peritoneal dialysis (PD) and 46 CKD stage 4] were stud-
ied. All survivors completed 40 months of follow-up. VC
was measured using multi-slice spiral CT of the super-
ficial femoral artery. Circulating osteoprotegerin (OPG),
Fetuin-A and high sensitivity C-reactive protein (hs-CRP)
were measured in addition to standard clinical biochemical
analysis.
Results. After a 40-month follow-up, 31 patients had died
(27 men and 4 women). Of 31 subjects, 31 had evidence
of significant VC. The majority of deaths were in the HD
group (48%), 36% were PD subjects and 16% were CKD
subjects. The outcome of interest was survival at the end
of follow-up. Multivariate logistical regression analysis re-
vealed male gender [OR 8.06 (1.34–48.450) P = 0.02],
OPG >25 pmol/L [OR 5.31(1.35–20.88) P = 0.02] and
hypoalbuminaemia [OR 0.26 (0.12–0.56) P < 0.01], were
associated with increased odds of death.
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